CervoMed Inc

Alexion Pharmaceuticals is engaged in the discovery and development of therapeutic products aimed at treating patients with an array of diseases, including hematologic and cardiovascular disorders, autoimmune diseases and cancer. Alexion's two primary product candidates, pexelizumab and eculizumab, are currently undergoing evaluation in several clinical development programs with the Federal Drug Administration. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs, through its wholly owned subsidiary, Alexion Antibody Technologies. During the fiscal year ended July 31, 2005, eculizumab was in Phase III clinical development for treatment of paroxysmal nocturnal hemoglobinuria , a chronic hematologic disease, and pexelizumab was in clinical development for two acute cardiac indications. Alexion is also pursuing additional potential indications for eculizumab and has other product candidates in earlier stages of development. Alexion Pharmaceuticals is based in Cheshire, Conn.

Finch Therapeutics Group, Inc., based in Boston, MA, is an early pioneer in the microbiome field, developing a portfolio of innovative microbiome assets aimed at various therapeutic areas. The company has made significant strides in microbiota transplantation studies, highlighting its commitment to advancing this promising new modality. In January 2023, Finch announced its decision to discontinue the Phase 3 trial of CP101 for recurrent C. difficile, redirecting its focus towards maximizing the value of its intellectual property estate and other assets. Recent developments include the resignation of key executives and a decision to delist from Nasdaq, underscoring the dynamic nature of its operational landscape. Generated from the website

Aegerion Pharmaceuticals, Inc is a biopharmaceutical company based in Cambridge, MA. Specializing in the development and commercialization of innovative therapies for rare diseases, the company focuses on addressing unmet medical needs in niche patient populations. With a commitment to research and development, Aegerion Pharmaceuticals, Inc strives to improve the lives of individuals living with rare diseases through the advancement of novel treatment options. By collaborating with healthcare professionals and patients, the company aims to make a meaningful impact in the field of rare disease management. Generated from their business information